Home World News FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent...

FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal

June 20, 2025

928

Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies